Legal & General Group Plc Acquires 6,392 Shares of Halyard Health, Inc. (HYH)

Legal & General Group Plc raised its holdings in shares of Halyard Health, Inc. (NYSE:HYH) by 9.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 71,313 shares of the medical instruments supplier’s stock after purchasing an additional 6,392 shares during the period. Legal & General Group Plc owned about 0.15% of Halyard Health worth $2,803,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. Bank of New York Mellon Corp increased its stake in Halyard Health by 0.4% during the second quarter. Bank of New York Mellon Corp now owns 885,238 shares of the medical instruments supplier’s stock valued at $34,772,000 after purchasing an additional 3,596 shares during the last quarter. SG Americas Securities LLC increased its stake in Halyard Health by 31.4% during the second quarter. SG Americas Securities LLC now owns 20,976 shares of the medical instruments supplier’s stock valued at $824,000 after purchasing an additional 5,015 shares during the last quarter. Arizona State Retirement System increased its stake in Halyard Health by 1.5% during the second quarter. Arizona State Retirement System now owns 19,700 shares of the medical instruments supplier’s stock valued at $774,000 after purchasing an additional 300 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in Halyard Health by 3.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 797,993 shares of the medical instruments supplier’s stock valued at $31,346,000 after purchasing an additional 27,421 shares during the last quarter. Finally, Sei Investments Co. increased its stake in Halyard Health by 38.1% during the second quarter. Sei Investments Co. now owns 18,245 shares of the medical instruments supplier’s stock valued at $717,000 after purchasing an additional 5,036 shares during the last quarter. Hedge funds and other institutional investors own 91.02% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/09/19/legal-general-group-plc-acquires-6392-shares-of-halyard-health-inc-hyh.html.

Halyard Health, Inc. (NYSE HYH) opened at 45.85 on Tuesday. Halyard Health, Inc. has a 52-week low of $31.59 and a 52-week high of $46.36. The stock’s 50 day moving average is $43.56 and its 200 day moving average is $39.64. The company has a market cap of $2.14 billion, a price-to-earnings ratio of 44.09 and a beta of 1.76.

Halyard Health (NYSE:HYH) last issued its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.51 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.37 by $0.14. The company had revenue of $399.20 million during the quarter, compared to analysts’ expectations of $399.16 million. Halyard Health had a return on equity of 8.29% and a net margin of 3.06%. The business’s revenue was down .2% on a year-over-year basis. During the same period last year, the business earned $0.45 earnings per share. On average, analysts predict that Halyard Health, Inc. will post $1.98 earnings per share for the current fiscal year.

Several analysts have weighed in on HYH shares. BidaskClub upgraded shares of Halyard Health from a “hold” rating to a “buy” rating in a research note on Saturday, August 19th. TheStreet upgraded shares of Halyard Health from a “c” rating to a “b” rating in a research note on Thursday, June 22nd. Stephens upgraded shares of Halyard Health from an “equal weight” rating to an “overweight” rating in a research note on Thursday, August 3rd. Deutsche Bank AG upped their price target on shares of Halyard Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Finally, Zacks Investment Research upgraded shares of Halyard Health from a “hold” rating to a “buy” rating and set a $44.00 price target for the company in a research report on Wednesday, July 12th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Halyard Health has an average rating of “Buy” and a consensus target price of $42.25.

Halyard Health Profile

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Institutional Ownership by Quarter for Halyard Health (NYSE:HYH)

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply